Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.605
-0.055 (-1.50%)
Aug 26, 2026, 4:00 PM EDT - Market closed

Anixa Biosciences Financials Overview

Millions USD. Fiscal year is Nov - Oct.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingApr '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Revenue
---0.21-0.51
Revenue Growth
------
Gross Profit
---0.05-0.13
Operating Income
-10.68-11.7-13.83-11.01-13.88-13.14
Net Income
-10.03-10.93-12.55-9.81-13.6-12.95
Earnings Per Share
-0.30-0.34-0.39-0.32-0.45-0.45
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingApr '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Cash & Investments
13.6915.1719.9223.8429.6935.73
Total Debt
0.180.20.230.180.220.26
Net Cash (Debt)
13.514.9719.6923.6729.4735.47
Net Cash Growth
-12.19%-23.98%-16.80%-19.67%-16.92%294.01%
Net Cash Per Share
0.410.460.620.760.971.24

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingApr '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Operating Cash Flow
-7.12-7.17-7.34-6.21-6.49-4.94
Capital Expenditures
------
Free Cash Flow
-7.12-7.17-7.34-6.21-6.49-4.94
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingApr '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Gross Margin
---23.33%-24.80%
Operating Margin
----5243.33%--2565.63%
Pretax Margin
----4728.57%--2564.06%
Profit Margin
----4671.91%--2530.08%
FCF Margin
----2956.67%--964.45%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Forward PE
-4.854.854.854.274.27
PS Ratio
---467.53-279.02